Is Momenta Pharmaceuticals' Stock a Buy?
Despite disruptions from the COVID-19 pandemic, Momenta Pharmaceuticals' (NASDAQ: MNTA) clinical trials investigating experimental therapies for a variety of autoimmune conditions and rare diseases are still going strong. The company will be announcing top-line phase 2 results for the treatment of myasthenia gravis (an autoimmune disorder affecting skeletal muscles) in the third quarter of 2020.
Will the company's pipeline candidates be successful in their clinical trials? Let's see what we can find out.
Image source: Getty Images.
Source Fool.com
